Early study shows Ebola vaccine to be safe
the ONA take:
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China, a new study published in the journal The Lancet has shown.
The Phase 1 study evaluated the safety of the vaccine in 120 healthy people in China's Jiangsu province. Participants received either a low dose or high dose of the vaccine, or placebo.
Participants were then monitored for over 28 days for any adverse events and an immune response. Results showed that no serious adverse events occurred and antibodies were significantly increased in participants.
Although the study did not demonstrate whether the immune response lasted longer than 28 days or whether a booster immunization would be needed, researchers say that the vaccine has potential.
Ad5-EBOV is not the only vaccination being studied to combat the Ebola virus, which has killed more 10,000 people since the beginning of 2014.
Other vaccines are currently in Phase III testing where they are being used in people at risk of infection in west Africa. The United Nations Ebola response team said this week that the Ebola outbreak should be gone by this summer.
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|